ROR1 and mantle cell lymphoma: In addition, the development of a new v1-specific anti-ROR1 Ab for IHC should reduce the amount of ROR1 tumour staining, which may impact it prevalence in MCL, DLBCL and FL by reducing the values shown at this point.